Utilization of elbasvir/grazoprevir (EBR/GZR) and adoption of resistance associated substitutions (RAS) testing in real-world treatment of HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)

According to the European label HCV GT1b infection as well as GT1a infection with baseline viral load (BVL)< 800,000 IU/mL can be treated with EBR/GZR for 12 weeks. For GT1a infection with BVL> 800,000 IU/mL baseline NS5A RAS-testing and lengthening of EBR/GZR to 16 weeks together with RBV is recommended if NS5A RAS are present or when RAS-testing is not available. The present analysis investigated the real-world utilization of these recommendations and the possible impact on EBR/GZR effectiveness in a large GT1 cohort of the German Hepatitis C Registry.